Thiazolidinedione-induced congestive heart failure

被引:42
作者
Cheng, AYY
Fantus, IG
机构
[1] Univ Toronto, Dept Med, Div Endocrinol & Metab, Toronto, ON M5C 2T2, Canada
[2] St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[3] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[4] Univ Hlth Network, Toronto, ON, Canada
关键词
cardiomyopathy; congestive heart failure; thiazolidinedione;
D O I
10.1345/aph.1D400
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To report 2 cases of thiazolidinedione (TZD) -associated congestive heart failure (CHF). As of March 13, 2004, one of the cases may represent the first description of TZD-associated cardiomyopathy in humans. CASE SUMMARIES: A 57-year-old obese white man with type 2 diabetes was treated with pioglitazone 30 mg/day and insulin. He had no prior history of CHF and had an excellent exercise tolerance. Over the first 4 weeks of pioglitazone therapy, the patient experienced significant weight gain and subsequently developed CHF and pulmonary edema. A 50-year-old obese white man with type 2 diabetes presented with cardiogenic shock. Rosiglitazone 4 mg once daily had been initiated 6 weeks prior to presentation. He had no prior history of cardiac disease, and investigations did not reveal a cause for the cardiogenic shock. Rosiglitazone therapy was discontinued on admission. He improved and was discharged 21 days later. DISCUSSION: TZDs are oral agents used for the treatment of type 2 diabetes. TZD-associated CHF and pulmonary edema have been reported in patients with a prior history of CHF. These 2 cases highlight that this adverse event can occur even in the absence of any preexisting history of clinical heart failure or cardiac disease. The second case may represent the first description of TZD-associated cardiomyopathy in humans. In both cases, an objective causality assessment using the Naranjo probability scale revealed that the adverse drug reaction between cardiomyopathy and rosiglitazone in this patient was probable. CONCLUSIONS: TZD should be considered as a cause in the differential diagnosis of CHIF and pulmonary edema in patients without a prior history of clinical CHF or cardiac disease. Healthcare professionals should be aware of the possible association between TZDs and cardiomyopathy.
引用
收藏
页码:817 / 820
页数:4
相关论文
共 21 条
  • [1] Donnelly R, 2001, DIABETES, V50, pA68
  • [2] *E LILL CAN, 2001, PROD MON ACT PIOGL H
  • [3] *E LILL CO, 2002, DEAR COLL LETT ACT T
  • [4] *GLAXOSMITHKLINE, 2001, PROD MON AV ROS MAL
  • [5] HANEFELD M, 2001, INT J CLIN PRACT S, V121, pS27
  • [6] Pulmonary edema associated with troglitazone therapy
    Hirsch, IB
    Kelly, J
    Cooper, S
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (15) : 1811 - 1811
  • [7] Obesity and the risk of heart failure
    Kenchaiah, S
    Evans, JC
    Levy, D
    Wilson, PWF
    Benjamin, EJ
    Larson, MG
    Kannel, WB
    Vasan, RS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (05) : 305 - 313
  • [8] Thiazolidinediones for type 2 diabetes - New agents reduce insulin resistance but need long term clinical trials
    Krentz, AJ
    Bailey, CJ
    Melander, A
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7256): : 252 - 253
  • [9] THE IMPACT OF OBESITY ON LEFT-VENTRICULAR MASS AND GEOMETRY - THE FRAMINGHAM-HEART-STUDY
    LAUER, MS
    ANDERSON, KM
    KANNEL, WB
    LEVY, D
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (02): : 231 - 236
  • [10] Differentiating members of the thiazolidinedione class: a focus on safety
    Lebovitz, HE
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2002, 18 : S23 - S29